Elevance Health on Track for Highest Close Since December 2022 — Data Talk
Elevance Health, Inc. (ELV) is currently at $532.91, up $23.94 or 4.7%
--Would be highest close since Dec. 12, 2022, when it closed at $534.18
--On pace for largest percent increase since July 14, 2023, when it rose 5.05%
--Currently up four consecutive days; up 7.12% over this period
--Longest winning streak since Feb. 16, 2024, when it rose for four straight trading days
--Best four day stretch since the four days ending July 21, 2023, when it rose 8.87%
--Up 2.77% month-to-date
--Up 13.01% year-to-date
--Down 2.53% from its all-time closing high of $546.77 on Oct. 31, 2022
--Up 17.14% from 52 weeks ago (April 20, 2023), when it closed at $454.93
--Would be a new 52-week closing high
--Up 28.68% from its 52-week closing low of $414.13 on July 12, 2023
--Traded as high as $537.66; highest intraday level since Dec. 13, 2022, when it hit $544.01
--Up 5.64% at today's intraday high; largest intraday percent increase since July 19, 2023, when it rose as much as 8.4%
--Third best performer in the S&P 500 today
All data as of 10:20:07 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 18, 2024 10:37 ET (14:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
10 Top-Performing Dividend Stocks
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters